159
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      scite_
      0
      0
      0
      0
      Smart Citations
      0
      0
      0
      0
      Citing PublicationsSupportingMentioningContrasting
      View Citations

      See how this article has been cited at scite.ai

      scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

       
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Weight loss, diarrhea, and polyneuropathy: could it be amyloidosis?

      Published
      case-report
      Bookmark

            Abstract

            Background:

            Amyloidosis is a multisystemic disease that may be hereditary, characterized by the deposit of amyloid in the extracellular space. Transthyretin-mediated (ATTRm) amyloidosis is the most common subtype of heredofamilial amyloidosis. The diagnosis is based on clinical suspicion and amyloid in tissues. Hepatic transplantation is the only treatment that prevents the synthesis of the amyloidogenic variants of transthyretin protein.

            Case Presentation:

            A 34-year-old male presented with weight loss, gastrointestinal symptomatology, and polyneuropathy associated with histopathologic deposits of amyloid in gastrointestinal and fat tissue as well as peripheral nerve.

            Conclusion:

            Hereditary familial amyloidosis (HFA) is a relatively rare disorder that leads to erroneous and delayed definitive diagnosis. Therefore, the diagnosis should be first based on a suspicion of the disease, and then proceed according to complete protocol.

            Main article text

            Background

            Amyloidosis is a range of diseases characterized by abnormal fibrous, intra and extracellular, proteinaceous deposits in organs and tissues termed amyloid. So far, 30 proteins and peptides have been identified as the main components of the amyloid [1,2]. Despite the obvious differences in primary sequences and structure, these amyloidogenic molecules all appear to share a common β-sheet conformation of their polypeptide that self-assemble perpendicular to the axis of the fibril. It is likely that this characteristic confers the fibrillar, proteolytic resistant, and insoluble characteristics to all forms of amyloid [3]. The relevance of amyloid depends on its extracellular accumulation grade, ranging from local microscopic deposits of no clinical significance to extensive, lethal infiltration of vital organs. Rudolph Virchow adopted the term “amyloid” in 1854, first introduced by Schleiden in 1838 to describe the vege­table starch, referring to the deposits of tissue material that stains in a similar way to cellulose when it is exposed to iodine [4]. There are several subtypes of amyloidosis, local and generalized forms, all with different amyloid precursors: AL (for Amyloid/Light chain) also called primary or myeloma-related, Amyloid A (AA) (for AA, so called because this serum AA was the first to be chemically characterized) also named secondary or reactive amyloidosis due to chronic inflammatory or neoplastic processes, and ATTR (for Amyloid/ transthyretin protein TTR, the acronymous of transthyretin an abnormal protein by a single amino acid) or familial amyloidosis (FA). TTR is a tetrameric plasmatic protein synthesized mainly in the liver and to a lesser extent in the choroid plexus and retina, responsible for transporting thyroxin and the protein linked to retinol. The estimated world prevalence of amyloidosis is 50,000 individuals with variable phenotypic presentations of the disease. Seventy-five percent present the primary form, 5% the secondary form and less than 5% develop an FA [1,4]. The hereditary pattern of the FA is the autosomal dominant, with its most prevalent type being mediated by transthyretin (ATTRm). Other recognized types include Aapo AI (Amyloid/Apolipoprotein AI), Aopo AII (Amyloid/ Apolipoprotein AII), and gelsolin (Agel) amyloidosis [5]. The latest systemic type of amyloidosis has been described and called leukocyte cell-derived chemotaxin 2 amyloidosis, which is highly prevalent in the Hispanic population, with a strong ethnic bias, affecting mainly Mexican people, Punjabis, people from the First Nations in British Columbia and native Americans [6]. The clinical picture of amyloidosis is hete­rogenous and nonspecific, determined by the affected organ or system. The diagnosis is based on clinical suspicion and the demonstration of the amyloid substance in tissues. A correct differential diagnosis is important since the management and prognosis may be completely different according to the source [7]. Additional tests such as immunohistochemistry, immunofluorescence, genetic tests and electron microscopy of amyloid deposits, assist in the or it helps in the identification of amyloidogenic protein, so that, familial forms of amyloidosis can be ruled out [8,9]. At present, Hepatic Trasplantation (HT) is the only treatment for the prevention of synthesis of amyloidogenic variants of TTR [10]. Here, we present a case of FA associated with cardiac, gastrointestinal, and neurologic affections.

            Case Presentation

            A 34-year-old male, without chronic illnesses, but with cocaine consumption for 6 weeks before hospital admi­ssion. Four years before admission he started with a dry cough associated with dyspnea and cyanosis. Thereafter, he presented nausea, postprandial vomiting, regurgitation, dyspepsia, and steatorrhea treated with loperamide (20-30mg). Eight months before admission he presented weight loss of 18 kg, erectile dysfunction, urinary incontinence, and paretic gait. Multiple laboratory tests (Table 1), along with endoscopies, histopathologic analysis, echocardiogram, and electromyography were performed but reported as normal (Table 2). Notably, all gastrointestinal and sural nerve biopsies analyzed were reported as normal. Consequently, a conclusive diagnosis was not reached. His mother has a history of chronic renal insufficiency probably secondary to amyloidosis. At the time of admission to our hospital, the physical examination of the patient revealed bilateral symmetric mydriasis with absent light and consensual reflexes, considerable muscular wasting, muscle weakness in all four extremities, absence of deep tendon reflexes in lower extremities, and bilateral symmetric hypoesthesia in a stocking distribution. Because of chronic diarrhea a small bowel series was performed, which reported accelerated intestinal transit (2 hours), and normal intestinal mucosa. Because of the mydriasis, a magnetic resonance imaging of the brain was performed, which showed hyperdense lesions in the frontal subcortical white matter with cortico-subcortical atrophy. An abdominal ultrasound revealed diffuse parenchymatous damage in the liver and chronic damage to the kidneys. An echocardiogram revealed non-obstructive symmetric hypertrophic myocardiopathy versus probable infiltration, with a left ventricular ejection fraction (LVEF) of 80%. Hence, given the presence of hypertrophic cardiomyopathy, disturbance of intestinal motility and autonomic and peripheral neuropathy, the possibility of a disease secondary to amyloid deposit was suspected. Therefore, biopsies from mucous membranes of the ileum and colon periumbilical fat, and sural nerve were obtained and processed to paraffin sections, stained with H&E,trichromic Masson method, and Congo red. The last staining was analyzed with a polarized light microscope. A kidney biopsy from a pediatric case of amyloidosis was used as a positive control of the Congo red stain. The histopathological findings revealed the presence of anacellular and irregular intense eosinophilic deposit observed interstitially in the periumbilical adipose tissue biopsy, probably corresponding to amyloid (Figure 1). In ileum biopsies, a similar eosinophilic deposit was observed at lamina propria, muscularis mucosae, and submucosa layer (Figure 2A), which exhibited a mixed blue and red staining with the trichromic method (Figure 2B). These eosinophilic and blue-red stained layers of ileum positive for Congo red staining (Figure 3C-D). In the sural nerve biopsy, a typical green-apple birefringence was found in cross-polarized light in Congo red-stained sections, located at endoneurium and in the arteriolar wall (Figure 3). The selectivity of this gold standard technique was confirmed in the positive control kidney histological sections (Figure 4). Therefore, a diagnosis of hereditary FA was presumed, but its precise confirmation has not yet been achieved, due to the abandonment of its study protocol.

            Table 1.
            Laboratory and immunologic studies.
            LABORATORY TESTPARAMETERRESULTREFERENCE VALUE
            Blood chemistryGlucose81 mg/dl70-100 mg/dl
            Creatinine0.92 mg/dl0.7-1.3 mg/dl
            AST26 UI0-35U/l
            ALT47 UI0-35 U/l
            AF6436-150 U/l
            LDH12760-160 U/l
            Total bilirubin0.57 mg/dl0.3-1.2 mg/dl
            Albumin3.4 g/l3.5-5.4 g/dl
            Cell blood countHemoglobin12 g/dl14-18 g/dl
            UrianalysispH5.04.6-8.0
            Urine density1.0251.003-1.030
            Erythrocytes10-15 × field0-2 × field
            BacteriaAbundantNegative
            Leukocytes20-300-10 × field
            24 hours urineCreatinine clearance164.49 ml/minute70-150 ml/minute
            Proteins0.30 g/24 hour0.01-0.30 g/24hour
            Bence jones proteinNegativeNegative
            Beta 2 microglobulin3.0 ug/ml<2.0 ug/ml
            Viral panelVIH/VHB/VHCNegativeNegative
            TorchToxoplasma/Rubeola/CMV/VHSNegativeNegative
            Toxinas A BNegativeNegative
            CoprologicpH6.55.8-6.4
            SugarsNegativeNegative
            BloodPositiveNegative
            Food without digestionNegativeNegative
            Fat in feces2.6 g/24 hour5 gr/24 hour
            Macroscopic parasitesNegativeNegative
            Coproparasitoscopic E. coli cystsNegative
            Fresh amebaNegativeNegative
            Stool cultureNormal enteric floraNormal enteric flora
            InmunoglobulinsIgG1,040 mg/dl700-1,800 mg/dl
            IgA128mg/dl100-480mg/dl
            IgM166 mg/dl60-250 mg/dl
            Anti DNA1:80Negative or until dilution 1:80
            ComplementC364 mg/dl80-200 mg/dl
            C419 mg/dl10-50 mg/dl
            Anti gliadin, anti endomysium, febrile reactions, PPD.NegativeNegative
            Figure 1.

            An acellular and irregular intense eosinophilic deposit was observed interstitially in the periumbilical adipose tissue biopsy, probably corresponding to amyloid. H&E stain 200×.

            Table 2.
            Ancillary test.
            EchocardiogramNonobstructive symmetric hypertrophic cardiomyopathy, probable amyloid infiltration, EFLV 80%, mild mitral insufficiency, mild tricuspid insufficiency without pulmonary hypertension.
            ElectromyographySensorimotor polyneuropathy of axonal and demyelinating type, more severe in lower extremities.
            ColonoscopyNormal terminal ileum and colon. Biopsies taken from both organs.
            EndoscopyModerate erosive gastritis with H. pylory. Sliding hiatal hernia.
            Biopsies of ileum and colonAmyloidosis in submucosa
            Biopsies of periumbilical fatAmorphous material compatible with amyloidosis.
            Figure 2.

            Photomicrographs of ileum biopsies. Note the presence of a deposit of eosinophilic material at lamina propria, muscularis mucosae, and submucosa layer (A), as well as their blue and red mixed stain with the trichromic method (B), and the congophilic stain of these ileum layer (C-D). A: H&E, B: Trichromic Masson method, C-D: Rojo Congo stain. A-C 100×, D 400×, total magnifications.

            Discussion

            Hereditary amyloidosis mediated by transthyretin (ATTRm) is a multisystemic disease conditioning diverse clinical manifestation (Table 3), which is transmitted in an autosomic dominant form with variable penetration. It is considered a rare disease, with a prevalence of less than 1 per 100,000 inhabitants. Presently, over 120 mutations are known to cause it. Mutation VAL30MET is the most frequent worldwide, being endemic in Portugal, Japan, and Sweden. Predominantly affects the neurologic system in 15% of patients, with an ascending sensori-motor, symmetric polyneuropathy which initiates in the lower extremities [11]. Cranial nerves are intact, except for those involved in pupillary reflexes, exhibiting festooned pupil, vitreous opacity, and glaucoma [2]. It may be linked to dysautonomia, presenting as orthostatic hypotension, erectile dysfunction, urinary incontinence, and gastrointestinal symptoms, with the latter arising either from direct involvement of the gastrointestinal system or amyloid infiltration of the autonomic nervous system, observed in up to 98% of cases [1]. It usually begins at the end of the second or third decade of life and up to 43% of the carriers present cardiac affection (conduction disturbances, atrial fibrillation, restrictive myocardiopathy and more often cardiac insufficiency) which is a frequent cause of mortality [12]. Other more unusual clini­cal manifestations are decreased peristalsis and dysphagia [6,13]. A confirmed diagnosis is based on a biopsy of the tissue or organ infiltrated where the typical birefringence of apple green color, stained by Congo red under polarized light fluoroscope is expected to be demonstrated. In case this is not possible, the recommendation is aspiration biopsy of abdominal subcutaneous fat (diagnostic yield of 70%-80%). Medullary biopsy stained for amyloid is posi­tive in 50% of the cases, and when combined with aspiration of subcutaneous fat, the yield may reach 80%-90%. The percentage of positivity for biopsy of rectal submucosa, kidney, liver, sural nerve, and heart is 75%, 94%, 97%, and 100%, respectively [12,14]. Until recently, the diagnosis of ATTR was essentially histologic. However, to facilitate the diagnosis, a multicentric international article was published in 2016, which put forth a new algorithm for the noninvasive diagnosis of ATTR, where the presence of classic signs of cardiac amyloidosis by image techniques, 2-3 degrees of uptake in gammagram Tc-DPD/PYP, along with the exclusion of a monoclonal protein, provides sensitivity and a positive predictive value of 100% for the diagnosis of ATTR [15,16]. The differential diagnosis should include diabetic neuropathy, chronic inflammatory demyelinating polyneuropathy, light chain (AL), amyloidosis by gelsoline, and apolipoprotein A1 [11]. The differentiation of the type of amyloidosis is carried out by immunohistoche­mistry using specific antibodies against the varied types of amyloid proteins: anti-AA, anti-light chains, anti-prealbumin, and anti-beta-2-microglobulin. In cases of hereditary FA, typing of transthyretin amyloid should be done [17]. To date, there is no approved specific therapy and hepatic transplantation (HT) is the only treatment for the prevention of the synthesis of amyloidogenic variants of TTR. The most accepted indications for HT are young patients, with VAL30MET mutation and being at the initial stage of the disease. Limitations for the procedure are: donor shortage, need for chronic immunosuppression, and advanced age at the time of presentation [4,10]. Post-transplant survival rate surpasses 50% at 20 years for patients with VAL30MET mutation and predominant neurologic manifestations. In contrast, patients with cardiac, leptomeningeal, and ocular amyloidosis may exhibit disease progression despite undergoing transplantation [15,16]. Nowadays, there are drugs that work at different points in the cascade of amyloidoge­nesis for TTR (Table 4), whose targets are suppression of synthesis, stabilization of TTR, and elimination of deposits. Several drugs are still in the last stages of experimentation for the specific treatment of this entity [15,16]. The dise­ase has an inexorable progressive course, leading to death 7-15 years after onset of clinical manifestations. If there is cardiac affection, the median survival is approximately 75 months after diagnosis [12,16].

            Figure 3.

            Photomicrographs of longitudinal nerve sections stained with Congo red. The characteristic apple- green birefringence of amyloid deposits was located at endoneurium (A, white arrows), and wall of small blood vessels (B, white arrows)- Note the red apple green birefringence, and dichroism coloration at arteriole wall (C, white arrows). Polarized light microscope. Congo red stain. A, B 200×; C, 1250×

            Figure 4.

            Photomicrographs of kidney biopsy from a pediatric case of amyloidosis. This specimen was used as positive control of the Congo red stain. White arrows point out the presence of amyloid deposits in the wall of intrarrenal blood vessels based on apple-green birefringence and dichroism characteristic of the molecular periodicity of amyloid. Polarized light microscope. Congo red stain. A,200×; B, 1,250×

            Table 3.
            Main clinical manifestations of FA.
            Clinical manifestations of FA
            Affected organManifestations
            CardiacHypertrophic of left ventricle (13%)Radio discordant voltage/mass
            Hypertrophic hypertensiveRadio discordant voltage/mass
            Intolerance to beta blockers
            CHF with preserved EFLV (10%)Not dilated hypertrophy of left ventricle
            Not complicated degenerative aortic stenosis (30%)Slow flow
            Low paradoxical gradient
            Thinning of atrioventricular valves
            NeurologicChronic inflammatory demyelinating polyneuropathy (15%)Neuropatic pain
            Symmetric
            neuropathy of upper extremities
            Idiopathic axonal polyneuropathyDysautonomia Erectile dysfuntion
            Carpal tunnel syndrome (33-49%)Neuropatic pain
            Autonomic neuropathy (10%)Orthostatic hypotension
            Recurrent urinary infections
            Urine retention
            Erectile dysfunction
            Sweating disturbances
            Motor neuropathy (18%)Decrease in amplitude of movements
            CNS (approx. 5%)Progressive dementia
            Headache
            Ataxia
            Epilepsy
            Spastic parylisis
            Stroke-like episodes
            Gastrointestinal Irritable colon syndromeChronic diarrhea
            Pseudo-obstructionNausea and vomiting
            Early satietyConstipation
            Involuntary weight loss
            OcularVitreum opacityGlaucoma
            Disturbances of conjunctival vesselsPapillary abnormalities
            RenalProteinuriaRenal failure
            Nephrotic syndrome

            Gertz et al. BMC Family Practice; Am J Manag Care. 2017;23:S107-S112.

            CHF: Congestive heart failure, EFLV: ejection fraction left ventricular, CNS: Central Neuronal System.

            Table 4.
            Drugs for treatment of ATTR.
            SUPPRESSION OF TTR SYNTHESISSTABILIZATION OF TTR B DISPOSAL OF DEPOSITSF
            HP
            Genetic mufflers: siARN (ALN-TTR)*, OAS (ISIS-TTRRX). a
            Tafamidisc
            Diflunisald
            Tolcaponee
            Doxycycline
            Doxycycline- TUDCA
            EGCG (green tea)
            PRX004
            Anti-SAP+CPHPC

            Adapted from diagnosis and treatment of transthyretin cardiac amyloidosis. Progress and hope. Rev. Esp. Cardiol. 2017. Available in http://dx.doi.org/10.1016/j.recesp.2017.05.018.

            AntiSAP + CPHPC: antibody against serum component P amyloid + (R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyI]pyrrolidine-2-carboxylic acid; EGCG: epigallocatechin-3 galato; OAS: antisense oligonucleotides; siARN: interference ARN, TTR: transthyretin; TUDCA: tauroursodeoxycholic acid.

            *siARN (ONPATTRO®): Approved by EMA for the treatment of AhTTR with polyneuropathy in stages 1 or 2.

            a, f Molecules under investigation for the treatment of patients with ATTR cardiac amyloidosis and AL.

            b Have demonstrated so far, their efficacy in ATTRm polyneuropathy.

            C Orfan drug approved by EMA to delay neurologic progression. The study ATTR-ACT, showed a decrease in mortality by 30% and in rate of hospitalization by 32%.

            d Non-esteroidal antiinflammatory that has demonstrated to stabilize the molecule of TTR in vitro.

            e Oral inhibitor of catechol-O-methyltransferase, which has a capacity to bind with TTR in vitro of patients with ATTRwt and Val122IIe.

            Conclusion

            The diagnostic protocol concluded that this was a case of hereditary FAwith cardiac affection, disturbance of intestinal motility, and autonomic and peripheralneuropathy. In this case, the patient had had studies done elsewhere before admission. Frequently, ATTR is an entity with substantial diagnostic mistakes or significant delay suntil the correct diagnosis is established. In our case, the reasons were diverse, varying from the heterogeneity of its presentation to the nihilistic consideration that limita presumptive diagnosis based on heuristics. Accordingly, since the onset of this disease is insidious and the clinical manifestations may vary widely depending on the organs or tissues affected, it is of paramount importance to emphasize that the diagnosis should be first basedon a suspicion that the disease may be present, and then go on with the consequent protocol.

            What is new?

            Although hereditary amyloidosis with gastrointestinal manifestations and polyneuropathy is widely described in the literature, few documented information regarding its association has been publicated in Mexican and Latin American population.

            Table summary

            The alterations in laboratories were positive urinalysis for erythrocytes 10 to 15 per field, creatinine clearance 164.49 ml/minute, beta 2 microglobulin 3, Eliminate “tool test with positive blood, coproparasitoscopic positive for E. coli cysts”, Anti DNA 1:80, complement C3 64.

            Echocardiogram with Nonobstructive symmetric hypertrophic cardiomyopathy probable amyloid infiltration, EFLV 80%, mild mitral insufficiency, mild tricuspid insufficiency. Electromyography with sensorimotor polyneuropathy of axonal and desmyelinating type, more severe in the lower extremities. Biopsies of ileum and colon with Amyloidosis in submucosa Biopsies of periumbilical fat with Amorphous material compatible with amyloidosis.

            In all patients with chronic diarrhea, weight loss and neuropathy, a directed search for intestinal biopsy should be performed.

            List of Abbreviations

            AA

            Amyloid A

            AL

            Light chains

            ATTRm

            Transthyretin mediated hereditary amyloidosis

            EFLV

            Ejection fraction left ventricular

            FA

            Familial amyloidosis

            Gammagram Tc-DPD/PYP

            Gammagram with 3,3-diphosphono-1,2-propanodicarboxilic/pyrophosphate tagged by technetium

            HP

            Hepatic transplantation

            TTR

            Transthyretin protein

            Conflict of interest

            The authors declare that there is no conflict of interest regarding the publication of this case report.

            Funding

            None.

            Consent for publication

            Not required.

            Ethical approval

            Ethical approval is not required at our institution to publish an anonymous case report.

            References

            1. Gertz MA. Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care. 2017. Jun;Vol. 23(7 Suppl):S107–12

            2. Shin SC, Robinson-Papp J. Amyloid neuropathies. Mt Sinai J Med. 2012. Vol. 79(6):733–48. [Cross Ref]

            3. Eanes ED, Glenner GG. X-ray diffraction studies on amyloid filaments. J Histochem Cytochem. 1968. Vol. 16:673–7. [Cross Ref]

            4. Sunde M, Serpell L, Bartlam M, Fraser PE, Pepys MB, Blake CC. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol. 1997. Vol. 273:729–39. [Cross Ref]

            5. Kyle RA. Amyloidosis: a convoluted story. Br J Haematol. 2001. Sep;Vol. 114(3):529–38. [Cross Ref]

            6. Gertz MA, Dispenzieri A. Systemic amyloidosis recognition, prognosis, and therapy: a systematic review. JAMA. 2020. Jul;Vol. 324(1):79–89. [Cross Ref]

            7. Nasr SH, Dogan A, Larsen CP. Leukocyte cell-derived chemotaxin 2-associated amyloidosis: a recently recognized disease with distinct clinicopathologic characteristics. Clin J Am Soc Nephrol. 2015. Nov;Vol. 10(11):2084–93. [Cross Ref]

            8. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016. Jun;Vol. 387(10038):2641–54. [Cross Ref]

            9. Chyra Kufova Z, Sevcikova T, Januska J, Vojta P, Boday A, Vanickova P, et al. Newly designed 11-gene panel reveals first case of hereditary amyloidosis captured by massive parallel sequencing. J Clin Pathol. 2018. Aug;Vol. 71(8):687–94. [Cross Ref]

            10. D’Aguanno V, Ralli M, Artico M, Russo FY, Scarpa A, Fiore M, et al. Systemic amyloidosis: a contemporary overview. Clin Rev Allergy Immunol. 2020. Dec;Vol. 59(3):304–22. [Cross Ref]

            11. Presnell SE, Schandl CA. Amyloidosis and unexpected death: a review of seven cases. Acad Forensic Pathol. 2016. Sep;Vol. 6(3):543–54. [Cross Ref]

            12. Reinés JB, Vera TR, Martín MU, Serra HA, Campins MM, Millán JM, et al. Epidemiology of transthyretin-associated familial amyloid polyneuropathy in the Majorcan area: son Llàtzer Hospital descriptive study. Orphanet J Rare Dis. 2014. Feb;Vol. 9(29):29[Cross Ref]

            13. Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 2015. Dec;Vol. 66(21):2451–66. [Cross Ref]

            14. Beses C. Sans-Sabrarfen. Capítulo 30: Gammapatías monoclonales. Clasificación. Métodos de detección. Gammapatía monoclonal de significado incierto. Amiloidosis primaria. Hematología Clínica. Amiloidosis primaria. 2007 Oct. 5th. Madrid, Spain: Elsevier. p. 628–33

            15. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017. Apr;Vol. 135(14):1357–77. [Cross Ref]

            16. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyr-etin amyloidosis. Circulation. 2016. Jun;Vol. 133(24):2404–12. [Cross Ref]

            17. González LE, López SÁ, Garcia PP. Diagnóstico y tratamiento de la amiloidosis cardiaca por transtiretina. Progreso y esperanza. Rev Esp Cardiol. 2017. Nov;Vol. 70(11):991–1004. [Cross Ref]

            Summary of the case

            1 Patient (gender, age) Male, 34 year-old.
            2 Final diagnosis Hereditary FA with cardiac, gastrointestinal and neuropatic affection.
            3 Symptoms Weight loss, gastrointestinal manifestations, peripheral and autonomic neuropathy.
            4 Medications Prednisone 1mg/kg/day and melphalan 0.15mg/kg/day.
            5 Clinical procedure Histopathologic study of gastrointestinal and adipose tissue and peripheral nerve.
            6 Specialty Internal medicine

            Author and article information

            Journal
            European Journal of Medical Case Reports
            EJMCR
            Discover STM Publishing Ltd.
            2520-4998
            30 August 2024
            : 8
            : 7
            : 139-145
            Affiliations
            [1 ]Department of Internal Medicine, Specialities Hospital National Medical Center La Raza IMSS, México City
            [2 ]Department of Pathology, Specialties Hospital National Medical Center La Raza, IMSS, México City, México
            [3 ]Department of Cell and Tissue Biology, Faculty of Medicine, National Autonomous University of México, México City, México
            Author notes
            [* ] Correspondence to: Zully Esmeralda Contreras Cortés Department of Internal Medicine, Specialities Hospital National Medical Center La Raza IMSS, México City. kch_lly109@ 123456hotmail.com
            Author information
            https://orcid.org/0000-0003-3937-159X
            Article
            ejmcr-8-139
            10.24911/ejmcr.173-1660235974
            9c01cd4f-d31a-4739-bc07-bffefd222524
            © Luis Francisco Pineda Galindo, Zully Esmeralda Contreras Cortés, Andrea Avila Martínez, María del Rosario Mora Campos, Elsa Acosta Jiménez, Armando Pérez Torres

            This is an open access article distributed in accordance with the Creative Commons Attribution (CC BY 4.0) license: https://creativecommons.org/licenses/by/4.0/) which permits any use, Share — copy and redistribute the material in any medium or format, Adapt — remix, transform, and build upon the material for any purpose, as long as the authors and the original source are properly cited.

            History
            : 11 August 2022
            : 10 February 2024
            Categories
            CASE REPORT

            Amyloidosis,biopsy ,diagnosis,polyneurophaty,familial amyloidosis

            Comments

            Comment on this article